CSF-1R targeted therapies for tenosynovial giant cell tumour: Current landscape and future developments
03 May 2021
bởiDr Margaret Shi
The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.
